Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse
No judgment, they will help you and ask you question that will benefit you
Looking for a Different Strength
One area of focus is long-term studies that follow patients over several years
US$ 26.95
US$ 28.82
US$ 26.04
US$ 23.19
US$ 24.13
